Incyte Stock Alpha and Beta Analysis

INCY Stock  USD 67.86  0.15  0.22%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Incyte. It also helps investors analyze the systematic and unsystematic risks associated with investing in Incyte over a specified time horizon. Remember, high Incyte's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Incyte's market risk premium analysis include:
Beta
0.45
Alpha
(0.08)
Risk
1.91
Sharpe Ratio
(0.02)
Expected Return
(0.03)
Please note that although Incyte alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Incyte did 0.08  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Incyte stock's relative risk over its benchmark. Incyte has a beta of 0.45  . As returns on the market increase, Incyte's returns are expected to increase less than the market. However, during the bear market, the loss of holding Incyte is expected to be smaller as well. Book Value Per Share is likely to rise to 17.48 in 2025. Tangible Book Value Per Share is likely to rise to 16.11 in 2025.

Enterprise Value

11.96 Billion

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Incyte Backtesting, Incyte Valuation, Incyte Correlation, Incyte Hype Analysis, Incyte Volatility, Incyte History and analyze Incyte Performance.
For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.

Incyte Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Incyte market risk premium is the additional return an investor will receive from holding Incyte long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Incyte. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Incyte's performance over market.
α-0.08   β0.45

Incyte expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Incyte's Buy-and-hold return. Our buy-and-hold chart shows how Incyte performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Incyte Market Price Analysis

Market price analysis indicators help investors to evaluate how Incyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Incyte shares will generate the highest return on investment. By understating and applying Incyte stock market price indicators, traders can identify Incyte position entry and exit signals to maximize returns.

Incyte Return and Market Media

The median price of Incyte for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 71.91 with a coefficient of variation of 3.2. The daily time series for the period is distributed with a sample standard deviation of 2.28, arithmetic mean of 71.35, and mean deviation of 1.96. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Acquisition by Harrigan Edmund of 3 shares of Incyte at 69.07 subject to Rule 16b-3
12/31/2024
2
Acquisition by Flannelly Barry P of 20144 shares of Incyte at 71.93 subject to Rule 16b-3
01/22/2025
3
Brokerages Set Incyte Co. Price Target at 75.71
02/14/2025
4
Grandfield Dodd LLC Acquires 682 Shares of Incyte Co.
03/03/2025
5
Essential Thrombocythemia Market to Witness Upsurge in Growth During the Study Period DelveInsight
03/05/2025
6
Acquisition by Cagnoni Pablo J of 44411 shares of Incyte at 64.25 subject to Rule 16b-3
03/06/2025
7
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635
03/07/2025
8
Incyte anuncia los resultados de sus ensayos clnicos de fase 3 que evalan el uso de ruxolitinib en crema al 1.5 percent en pacientes con prurigo nodular en la R...
03/10/2025
9
Incyte Up 2.6 percent Since Last Earnings Report Can It Continue
03/12/2025

About Incyte Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Incyte or other stocks. Alpha measures the amount that position in Incyte has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2022 2023 2024 2025 (projected)
Payables Turnover0.752.331.581.66
Days Of Inventory On Hand213.2990.1468.8665.41

Incyte Upcoming Company Events

As portrayed in its financial statements, the presentation of Incyte's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Incyte's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Incyte's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Incyte. Please utilize our Beneish M Score to check the likelihood of Incyte's management manipulating its earnings.
13th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Incyte

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Incyte Stock Analysis

When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.